Investment analysts at StockNews.com began coverage on shares of Oragenics (NYSE:OGEN – Get Free Report) in a research report issued on Sunday. The brokerage set a “sell” rating on the stock.

With over 5 million concussions occurring annually in the U.S. alone, there is a significant unmet need for effective diagnostic and therapeutic solutions. This partnership positions Oragenics and ...

Oragenics (OGEN) announced a strategic partnership with BRAINBox Solutions. This collaboration seeks to develop the first intranasal therapy ...

Investment analysts at StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN – Get Free Report) in a report issued on Saturday. The firm set a “sell” rating on the stock. Oragenics Stock ...

This article was generated by Benzinga's automated content engine and reviewed by an editor.

European shares were mixed today. The eurozone's STOXX 600 rose 0.2%, Germany's DAX 40 slipped 0.1% and France's CAC 40 fell ...

The shares closed the day at $367.74, down 8.3% from previous close. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the ...

Nvidia stock (NVDA) clawed back some losses Tuesday after Monday's DeepSeek-fueled 17% crash. At the end of the trading day, Nvidia stock stood 8.9% higher at $128.99. The move helped stoke a ...